Low-Dose CDK4/6 Inhibitors Induce Presentation of Pathway Specific MHC ligands as Potential Targets for Cancer Immunotherapy

Authors

Klatt, Martin Gunther

Scheinberg, David A.

Description

Description from PRIDE: "Cyclin dependent kinase 4/6 inhibitors (CDK4/6i) lead to cell-cycle arrest but also trigger T cell-mediated immunity, which might be mediated by the qualitative and quantitative changes in human leukocyte antigen (HLA) ligands on the cancer cell surface. We investigated the effects of CDK4/6i, Abemaciclib and Palbociclib, on the immunopeptidome at subclinical, non-toxic,...

Subject

Breast Neoplasms

Cyclin-Dependent Kinase 4

Cyclin-Dependent Kinase 6

Cyclin-Dependent Kinase Inhibitor p16

Cyclin-Dependent Kinase Inhibitor p18

HLA Antigens

T-Lymphocytes

Access Rights

Free to All